Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis ...

INGELHEIM, Germany, June 8, 2026 /CNW/ - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), ...
The New York Times

Where do Braden Schneider and the Rangers stand after arbitration filing, trade rumors?

Braden Schneider could still be moved for an impact forward this offseason. Wendell Cruz / Imagn Images The NHL Draft and free agency brought a flurry of New York Rangers roster moves as team ...
Comic Book Resources on MSN

10 most powerful cards in Disney Lorcana's Attack of the Vine

The highly-anticipated 13th set from Disney Lorcana is on the horizon and these 10 Attack of the Vine cards are must-haves ...